We have seen and will continue to see dramatic changes within the field of oncology. Whilst the burden of disease is set to increase, the available armamentarium to the oncologist will be greater, more robust and offer the potential to focus on individual needs. Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic, policy and real world issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting. Topics addressed include: Profiles of new anticancer agents Protocols of on-going studies Selective and 'personalized' approaches Clinical implications and applications for new immunotherapies, radiotherapies and biomarkers Integration of diagnostic and therapeutic approaches Impact of molecular genetics on prevention, screening, diagnosis and treatment Screening programs and methodology Biological processes involved in cancer and how new understanding will impact treatment Current debates on policy and treatment guidelines Real world data and outcomes research The journal welcomes unsolicited article proposals.
我们已经看到并将继续看到肿瘤学领域的巨大变化。虽然疾病负担将增加,但肿瘤学家可用的医疗设备将更大、更坚固,并有可能专注于个人需求。未来肿瘤学(ISSN1479-6694)为癌症治疗的新时代提供了一个论坛。该杂志关注最重要的进展,并强调其在临床环境中的相关性。此外,未来肿瘤学以简洁、一目了然的文章格式提供基本信息,这对于向时间日益有限的社区提供信息至关重要。 该杂志对科学和临床问题,以及经济、政策和现实世界问题采取了前瞻性的立场,我们在这个癌症治疗的新时代所面临的问题。该杂志包括文献意识,如放射治疗和免疫治疗的最新进展,简明的评论和分析,以及全面的评论文章,所有这些都提供了关键的发现,转化为临床环境。 讨论的主题包括: 新型抗癌剂概况 正在进行的研究的方案 选择性和“个性化”方法 新免疫疗法、放射疗法和生物标志物的临床意义和应用 诊断和治疗方法的整合 分子遗传学对预防、筛选、诊断和治疗的影响 筛选方案和方法 癌症的生物学过程以及新的认识将如何影响治疗 关于政策和治疗指南的当前辩论 现实数据和结果研究 该杂志欢迎不请自来的文章建议。
期刊ISSN
|
1479-6694 |
最新的影响因子
|
3.3 |
最新CiteScore值
|
1.78 |
最新自引率
|
6.00% |
期刊官方网址
|
http://www.futuremedicine.com/loi/fon |
期刊投稿网址
|
http://www.futuremedicine.com/page/submitarticle |
通讯地址
|
FUTURE MEDICINE LTD, UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, ENGLAND, N3 1QB |
偏重的研究方向(学科)
|
ONCOLOGY- |
出版周期
|
Monthly |
平均审稿速度
|
偏慢,4-8周 |
出版年份
|
2005 |
出版国家/地区
|
ENGLAND |
是否OA
|
No |
SCI期刊coverage
|
Science Citation Index Expanded(科学引文索引扩展) |
NCBI查询
|
PubMed Central (PMC)链接 全文检索(pubmed central) |
最新中科院JCR分区
|
大类(学科)
小类(学科)
JCR学科排名
医学
ONCOLOGY(肿瘤学) 3区
160/223
|
|||||||
最新的影响因子
|
3.3 | |||||||
最新公布的期刊年发文量 |
|
|||||||
总被引频次 | 4053 | |||||||
特征因子 | 0.008290 | |||||||
影响因子趋势图 |
2007年以来影响因子趋势图(整体平稳趋势)
|
最新CiteScore值
|
1.78
=
引文计数(2018)
文献(2015-2017)
=
1749次引用
982篇文献
|
||||||||||
文献总数(2014-2016) | 982 | ||||||||||
被引用比率
|
61% | ||||||||||
SJR
|
0.759 | ||||||||||
SNIP
|
0.547 | ||||||||||
CiteScore排名
|
|
||||||||||
CiteScore趋势图 |
CiteScore趋势图
|
||||||||||
scopus涵盖范围 |
scopus趋势图
|
本刊同领域相关期刊
|
|
期刊名称 | IF值 |
NEURO-ONCOLOGY | 15.9 |
JOURNAL OF NEURO-ONCOLOGY | 3.9 |
OncoImmunology | 7.2 |
JOURNAL OF IMMUNOTHERAPY | 3.9 |
Cancer Immunology Research | 10.1 |
Infectious Agents and Cancer | 3.7 |
CANCER IMMUNOLOGY IMMUNOTHERAPY | 5.8 |
INTEGRATIVE CANCER THERAPIES | 2.9 |
Hormones & Cancer | 3 |
本刊同分区等级的相关期刊
|
|
期刊名称 | IF值 |
JOURNAL OF NEURO-ONCOLOGY | 3.9 |
INTEGRATIVE CANCER THERAPIES | 2.9 |
Hormones & Cancer | 3 |
Frontiers of Medicine | 8.1 |
Molecular Medicine Reports | 3.4 |
American Journal of Translational Research | 2.2 |
BREAST | 3.9 |
Breast Cancer | 4 |
Breast Journal | 2.1 |
分享者 | 点评内容 |
发表日期:2018-02-08 |
审稿时间:3个月内
接收率: 中等(50%命中)
文章顺利接受,给大家分享下。我投稿到接受三个月时间,编辑很nice,只是小修,不需要版面费,如果想加快发表速度,可以交550英镑左右。
(0)
|
发表日期:2017-09-30 |
审稿时间:2个月内
接收率: 中等(50%命中)
投稿不到两个月就接收了,编辑还帮我免费润了色,版面费也不需要,超级赞!
(0)
|